Join
Live feed
·
PRReleasevia Quantisnow
Assembly Biosciences Inc. logo

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

ByQuantisnow·Wall Street's wire, on your screen.
ASMB· Assembly Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ASMB (Assembly Biosciences Inc.) and more on Quantisnow.